9 new development(s) in neoantigen vaccines today.
On August 19, 2026, a single piece of clinical data sent Moderna's stock soaring 177% in one day—one of the largest single-day gains for an S&P 500 constituent in more than two decades. The personalized mRNA cancer vaccine intismeran autogene, co-developed by Moderna and Merck, m…
Test your knowledge with our new weekday mini crossword Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we look at how a C…
By The ASCO Post Staff Posted: 8/21/2026 10:29:00 AM Last Updated: 8/21/2026 9:47:23 AM Advertisement Merck and Moderna, Inc. have announced positive topline results from the phase III INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) evaluating adjuvant treatment w…
Moderna and Merck say their personalized mRNA cancer vaccine significantly reduced the risk of melanoma returning or spreading. Get up-to-the-minute news sent straight to your device. Account processing issue - the email address may already exist Must be at least 8 characters, no…
Test your knowledge with our new weekday mini crossword Matthew Herper covers medical innovation — both its promise and its perils. Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as…
What Is A Neoantigen Cancer Vaccine? The Science Behind Moderna-Merck's Melanoma Breakthrough NDTV Profit
NTxscribe CORE automates mRNA amplification of patient-derived tumor transcriptome, preserving full-length range of each patient’s tumor sequences in a personalized cancer vaccine workflow that is now dosing patients RIO RANCHO, N.M.--(BUSINESS WIRE)--NTx Bio, a leader in next-ge…